Roche In New Phase III Bet On MorphoSys' Anti-Amyloid Agent
Roche is taking a punt on a new Phase III trial with gantenerumab in patients with mild Alzheimer's despite ending one called SCarlet RoAD in similar patients just over two years ago.
You may also be interested in...
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.